Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
NX-5948
Advertisement
Nurix Shows Promising CSU Data for Bexobrutideg
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Bexobrutideg Shows Strong Phase 1 Results in WM Trial
BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...
Advertisement
